Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention

NCT06750523 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-01-01

No results posted yet for this study

Summary

All factors that influence the peak bone mass achieved at skeletal maturity are important in determining an individual's risk of developing osteoporosis later in life. Bone health begins with maternal health and nutrition, which influence skeletal mass and bone density in utero. The mechanisms underlying the effect of the intrauterine environment on bone health are currently unknown, but certainly include 'fetal programming' of oxidative stress and endocrine systems, as these influence skeletal growth and development later in life.

For the prevention of bone health, the challenges rely 1) in the need for new technology and software specific and applicable to the fetus and newborn; 2) in establishing the effect of environmental contaminants, in particular endocrine disruptors, oxidative stress and subsequent epigenetic changes in mothers and subsequently on the fetus, newborn and infant.

Conditions

  • Low-Risk Pregnant Women at Full-Term Gestation
  • Healthy Fetal Population
  • Healthy Neonatal Population

Interventions

DIAGNOSTIC_TEST

Cord blood sampling

A cord blood sample will be taken at birth for analysis of oxidative stress markers, endocrine disruptors, and microRNAs.

DIAGNOSTIC_TEST

urine sampling

At one month of age, urine samples will be collected from newborns to analyze oxidative stress markers and endocrine disruptors.

BEHAVIORAL

Life style questionnaire

At the time of enrollment, mothers will complete a specialized questionnaire designed to assess potential exposure to endocrine disruptors (EDCs) through diet, clothing, and the use of cosmetics and detergents.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria di Parma

    collaborator OTHER
  • Azienda Ospedaliera Universitaria Policlinico "G. Martino"

    collaborator OTHER
  • University of Parma

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
37 Weeks
Max Age
42 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-17
Primary Completion
2025-06-30
Completion
2025-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06750523 on ClinicalTrials.gov